Clearmind Medicine obtains IND approval from FDA to start Phase I/IIa trial

Clearmind Medicine announced that the U.S. Food and Drug Administration, FDA, has cleared the Company’s Investigational New Drug, IND, application for its proprietary MEAI-based CMND-100 oral capsule, allowing the Company to proceed with a Phase I/IIa clinical trial in the United States for treating patients with alcohol use disorder, AUD. While the Phase I/IIa clinical trial was already approved in Israel, clearance from the FDA will allow the trial to be initiated in the US. The Company has signed agreements to perform the Phase I/IIa clinical trial in leading universities in the United States, Yale School of Medicine’s and the Johns Hopkins University School of Medicine. The Israeli trial will be conducted at the IMCA in the Tel Aviv suburb of Ramat Gan.